Dec. 20 (Bloomberg) --
...
Panacos Pharmaceuticals Inc. (PANC US) fell $1.70, or 30 percent, to $3.99 and traded as low as $3.58. The drugmaker said preliminary results from a study showed its drug candidate for the treatment of HIV, bevirimat, missed its expectations.
...
...
Panacos Pharmaceuticals Inc. (PANC US) fell $1.70, or 30 percent, to $3.99 and traded as low as $3.58. The drugmaker said preliminary results from a study showed its drug candidate for the treatment of HIV, bevirimat, missed its expectations.
...